Q-omics provides the consensus-scored TCP11L2 profile across patient tissues and cancer cell-line models. TCP11L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TCP11L2 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, TCP11L2 RNA expression shows 19,974 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUSC, and UVM as cancer lineages where TCP11L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCP11L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCP11L2 survival associations across molecular data types. TCP11L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCP11L2 RNA expression–survival associations across cancer types. High TCP11L2 expression shows unfavorable associations in LIHC, but favorable associations in HNSC, KIRC, ACC, SKCM and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TCP11L2 RNA expression.
This table summarizes TCP11L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TCP11L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCP11L2 shows lower tumor expression in LUSC, LUAD, HNSC, BRCA, THCA and READ. The LUSC box plot shows higher TCP11L2 RNA expression in normal versus tumor tissue (log2 FC = −1.214, t-test p < 0.001).
This table shows molecular features associated with TCP11L2 in patient tissues and cancer cell lines. In patient samples, TCP11L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCP11L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
